Grifols S.A.
Healthcare · EUR · BME
Price
€9.523
Cap
€6.10B
Earnings
—
30d Trend
+6.8%
32% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 58×Macro 0.99 (−1%)=57
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Potential value play — but fundamentals need strengthening
BRAIN47'S ASSESSMENT
I rate Grifols S.A. at 57/100 — a STRONG reading on the Brain47 Signal. The strongest factor is fundamentals at 62/100. I classify this as a growth position with the strongest thesis on a long-term horizon.
PAST PERFORMANCE
1 MONTH
-0.4%
3 MONTHS
-5.6%
12 MONTHS
+11.5%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Potential value play — but fundamentals need strengthening. Fundamentals (62) and Momentum (59) are the primary strengths. I note that quality is the weakest area at 40/100 — this warrants monitoring. Historical volatility is moderate at 32%. I classify this as a growth position — positive trend direction combined with solid fundamentals points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.